For decades, the US healthcare system has struggled to address the diet-related chronic illnesses affecting nearly half of ...

This is just a tiny glimpse of the data available to CivicScience clients. Discover more data. CivicScience has data on over ...

Advocates say microdosing reduces costs and side effects while maintaining weight loss, then can help with weight maintenance. The approach is especially popular among telemedicine physicians, who ...

CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

The number of prescriptions for anti-obesity GLP-1 drugs like Wegovy and Ozempic is rising in North Carolina, just as it is ...

They're known to aid in blood sugar control and, now, weight loss — but, according to a sweeping new study, the popular GLP-1 ...

Nephrologists jumped on the GLP-1 bandwagon well before Novo Nordisk won FDA approval for Ozempic in chronic kidney disease ...

Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...

A majority with overweight/obesity discontinue within a year, but the rate is higher among those without type 2 diabetes.

Novo Nordisk's CEO is not worried about blockbuster semaglutide drugs being added to Medicare drug pricing negotiations this ...

Eli Lilly Chief Corporate Brand Officer Lina Polimeni on how the brand differentiates itself in the crowded pharma market, ...

A small percentage of patients taking GLP-1 medications have experienced vision problems, but a direct causal link with the ...